Breast Cancer Market Is Expected To Grow At a CAGR Of 9.2% During Forecasted Period 2017-2023

Pune, India, July 13, 2017 /MRFR Press Release/- Market Research Future published a half-cooked research report on global breast cancer market.

Market Highlights

Breast cancer is one of the major type of cancer in women. To ensure the effective treatment of the patient early stages diagnosis of the breast cancer is important. According to WHO, 200,000 new cases are diagnosed worldwide and the number will increased in the coming future. Different types of treatments are available but there is no absolute treatment. Global breast cancer market is driven by increasing prevalence of breast cancer which is due to adoption of unhealthy lifestyle, genetic profile of the patients and continuous exposure to harmful radiations. Increasing government support and awareness also contributed in the growth of the market. But side effect associated with the therapy and high cost of treatment has hamper the growth of the market.

Global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.

Report Details @ https://www.marketresearchfuture.com/reports/global-breast-cancer-market-1379

Figure 1- Global breast cancer market, by treatment

 Source- Annual reports, Press release, White paper, Company Presentation

Segmentation:

Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.

Competitive Analysis

 Sources- Annual reports, Press Release, White paper, Company Presentation

The major key player for the global breast cancer market are Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)

Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Some major players has adopted strategies of acquisitions and strategic alliances for the growth of the market. Moreover, competition amongst new market players is also expected to upsurge growth for breast cancer drugs market over the next seven years.

Pfizer is among the world's largest pharmaceutical companies headquartered in US. In March 2017, company has got FDA approval of IBRANCE for the first line HR+, HER2- metastatic breast cancer. It is the only cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the FDA as a first line therapy. In 2016, Pfizer has acquired Medivation to increase its oncology market.AstraZeneca is an Anglo–Swedish multinational pharmaceutical company headquarters in UK. In 2017, company has got approval for three new drugs. Lynparza is one of three new drugs which is PARP inhibitors. This drug has shown a most promising results in Phase III clinical trials and may generate $1.2 billion by 2020.Novartis AG is one of the largest Swiss pharmaceutical company. In 2017, company has got FDA approval for Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer with the combination of any aromatase inhibitor. Company has announced collaboration with IBM Watson Health to explore development of new techniques. In 2016, LEE011 is approved by FDA as first-line treatment for breast cancer.GlaxoSmithKline is the world sixth largest pharmaceutical company headquartered in UK. Tykerb is the most widely used drug of the company. In 2015, GSK has announced its acquisition on GlycoVaxyn which is a Swiss pharmaceutical company. F. Hoffmann-La Roche AG is among the five largest pharmaceutical company in the world headquartered in Switzerland. In 2014, Roche has got an FDA approval of Kadcyla (trastuzumab emtansine) which is the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand,

Market Research Future

Office No. 524/528, Amanora Chambers

Magarpatta Road, Hadapsar

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com